Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 7/20 | 0.68 |
| ▸ | AKR1A1 | P14550 | 3/20 | 0.68 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11001789 | 0.81 | AKR1B1 (1.00) | AKR1B1AKR1A1ITGA4 | |
| SCHEMBL10930167 | 0.74 | AKR1A1 (1.00) | AKR1B1AKR1A1CYP2C9HTR2AITGA4 | |
| SCHEMBL3035791 | 0.74 | ITGA4 (0.63) | AKR1B1AKR1A1PDE7ACYP2C9HTR2A | |
| SCHEMBL2265588 | 0.74 | IDO1 (0.53) | AKR1B1AKR1A1PDE7AIDO1HTR2A | |
| SCHEMBL25892728 | 0.73 | AKR1B1 (0.82) | AKR1B1AKR1A1ITGA4 | |
| SCHEMBL10853344 | 0.73 | AKR1B1 (0.50) | AKR1B1AKR1A1PDE7AIDO1 | |
| SCHEMBL9673837 | 0.73 | AKR1A1 (0.82) | AKR1B1AKR1A1ITGA4 | |
| SCHEMBL1722012 | 0.73 | PGR (0.69) | AKR1B1PDE7AIDO1 | |
| SCHEMBL8913575 | 0.73 | IDO1 (0.51) | AKR1B1AKR1A1PDE7AIDO1HTR2A | |
| SCHEMBL10656869 | 0.72 | AKR1B1 (1.00) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| EP-1891075-B1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | MERCK SERONO SA (CH) | 2011-10-19 | — | — | EP | disclosed |
| EP-1891075-B1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | MERCK SERONO SA (CH) | 2011-10-19 | — | — | EP | disclosed |
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | LABORATOIRES SERONO S.A. (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | LABORATOIRES SERONO S.A. (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | LABORATOIRES SERONO S.A. (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-1891075-A1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125784-A1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | disclosed |
| EP-0127412-B1 | IMIDAZOLIDINEDIONE DERIVATIVES | PFIZER INC. (US) | 1990-10-17 | — | — | EP | disclosed |
| US-4533667-A | FOR TREATMENT OF DIABETES | PFIZER INC. (US) | 1985-08-06 | — | — | US | disclosed |
| EP-0127412-A2 | Imidazolidinedione derivatives | PFIZER INC. (US) | 1984-12-05 | — | — | EP | disclosed |
| US-4464380-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1984-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | RORB, NR3C2, NR1H2 | AKR1B1 109/4885AKR1A1 160/4885PDE7A 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.